These antitumor properties are also demonstrated by a number of sartans, selective Ang II AT1-receptor antagonists [94-101], further reinforcing that blockade of AT1R could be an effective anticancer strategy, not only because these drugs target cancer cells, but also endothelial cells at the tumor and stroma. This evidence concerns the gene AGTR1 and neoplasm.